Lilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer's Disease
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
J.P. Morgan sees recent Eli Lilly (LLY) weakness as opportunity ahead of Donanemab Ph3 Data
March 9, 2023 1:01 PM ESTJ.P. Morgan reiterated an Overweight rating and a $400.00 price target on Eli Lilly and Company (NYSE: LLY) ahead of the upcoming release of the donanemab ph3 data.
Analyst Chris Schott wrote in a note, Following recent LLY weakness, we have been receiving a number of questions on the story and wanted to provide our updated thoughts on upcoming donanemab ph3 data as well as... More
